- Home
- /
- Tesamorelin 10mg
Tesamorelin 10mg
Certificate of Analysis
HPLC + Mass Spectrometry included with order
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids. It is the only GHRH analogue to have received FDA approval (as Egrifta) for a specific clinical indication — reduction of excess abdominal fat in HIV-associated lipodystrophy.
In research settings, Tesamorelin is studied for its potent stimulation of endogenous growth hormone production while maintaining the natural pulsatile release pattern. Published studies have examined its effects on visceral adipose tissue, hepatic fat content, IGF-1 levels, and cognitive function in ageing populations.
Tesamorelin represents a well-characterised GHRH analogue with an extensive published research profile spanning over a decade of clinical investigation.
Independently Verified Purity: 99.236%
Tested by Janoshik Analytical (Prague) — Task #72996, 31 July 2025.
Actual content: 11.60mg per vial (16% overfilled vs stated 10mg dose).
Verification: janoshik.com/verify — Key:
HE27MPB2UT68
Specifications
| Molecular Weight | 5135.89 g/mol |
| CAS | 804475-66-9 |
| Sequence | 44 amino acid GHRH analogue (trans-3-hexenoic acid modification) |
| FDA Status | Approved as Egrifta (clinical use — not sold here for that purpose) |
| Appearance | White lyophilised powder |
| Storage | 2-8°C, protect from light |
This product is sold strictly for in-vitro research and laboratory purposes. Not for human or animal consumption. Not evaluated by the MHRA or FDA. Must be 18+ to purchase. By purchasing, you agree to our Research Disclaimer and Terms of Service.
| Catalogue Number | KYR-TESAMORELIN10MG |
| Compound Name | Tesamorelin 10mg |